Hyalart (Sodium Hyaluronate)

Hyalart is indicated for the symptomatic management of osteoarthritis in weight‑bearing joints where conservative therapy has been insufficient.

• Knee osteoarthritis in adults with mild to moderate disease.
• Hip osteoarthritis in patients who are not candidates for immediate joint replacement.
• Adjunct to physical therapy and analgesic regimens to improve joint function.
• May be considered when intra‑articular corticosteroids are contraindicated or have failed.
• Used to delay the need for surgical intervention in appropriate candidates.
• Can be administered in a series of injections spaced several weeks apart as recommended by the treating physician.

• Sodium hyaluronate in Hyalart mimics the natural hyaluronic acid component of synovial fluid. When injected intra‑articularly, it integrates into the joint space, restoring the viscoelastic properties of the fluid. This improves lubrication, enhances shock‑absorbing capacity, and may stimulate endogenous production of proteoglycans, thereby supporting cartilage health and reducing mechanical stress on the joint surfaces and contributes to a more physiological joint environment.

Adverse reactions to intra‑articular sodium hyaluronate are generally mild, but serious events can occur.

Common

• Injection site pain – typical mild discomfort after the procedure.
• Swelling of the treated joint, usually resolving within days.
• Warmth or mild erythema at the injection site.
• Transient stiffness lasting a few hours.
• Headache or mild flu‑like symptoms.
• Mild fever within 24 hours of injection.

Serious

• Septic arthritis or other joint infection requiring medical treatment.
• Allergic reaction including anaphylaxis, urticaria, or angioedema.
• Severe inflammatory reaction with persistent swelling and pain.
• Hemarthrosis (bleeding into the joint space).
• Deep vein thrombosis or pulmonary embolism temporally associated with injection.
• Persistent severe pain lasting more than a week.

Before using Hyalart, clinicians should evaluate patient history and joint condition to minimize risks.

• Confirm diagnosis of osteoarthritis and assess severity before injection.
• Avoid use in patients with active joint infection or systemic infection.
• Exercise caution in individuals with known hypersensitivity to hyaluronic acid or any component of the formulation.
• Do not inject into a joint with severe inflammatory arthritis such as rheumatoid arthritis without specialist guidance.
• Consider postponing treatment during pregnancy or lactation due to limited safety data.
• Evaluate renal or hepatic impairment as altered clearance may affect systemic exposure.
• Ensure proper aseptic technique to reduce infection risk.

Hyalart may interact with other agents administered intra‑articularly or systemically; clinicians should review concomitant therapies.

Avoid

• Concurrent intra‑articular corticosteroids within 4 weeks, which may diminish the effect of sodium hyaluronate.
• Use with intra‑articular antibiotics or other viscosupplements in the same joint session.
• Avoid simultaneous intra‑articular hyaluronate injections in multiple joints within the same treatment cycle.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to potential increased bleeding risk at the injection site.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask early signs of joint infection.
• Disease‑modifying antirheumatic drugs (DMARDs) in patients with inflammatory arthritis, requiring close monitoring.
• Consider temporary discontinuation of intra‑articular steroid injections if the patient is receiving biologic therapy.